Close

TG Therapeutics (TGTX) Launches Phase 1/2 Study of TGR-1202 and Carfilzomib in Relapsed or Refractory Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. V
8. IBM
9. KMB
10. HCP


Go back to TG Therapeutics (TGTX) Launches Phase 1/2 Study of TGR-1202 and Carfilzomib in Relapsed or Refractory Lymphoma